Latest Juvenile myelomonocytic leukemia Stories
For patients with myelodysplastic syndromes (MDS), choosing the appropriate treatment depends heavily on the prognosis.
An experimental drug lessens symptoms of a rare form of childhood leukemia and offers significant insight into the cellular development of the disease, according to findings from a new UCSF study.
An experimental drug lessens symptoms of a rare form of childhood leukemia and offers significant insight into the cellular development of the disease.
For blood cancer patients at high risk of relapse, hematopoietic stem cell transplantation (HSCT), the transplantation of blood-forming stem cells, is one of best options for treatment and a potential cure.
A UCSF-led team has discovered a direct link between an inherited genetic mutation, a set of developmental abnormalities and a rare form of childhood leukemia called juvenile myelomonocytic leukemia, or JMML.
Discovery will enable doctors to accurately diagnose and treat skin rashes in bone marrow transplant patients and personalize GVHD treatment.
For the first time, researchers at Fred Hutchinson Cancer Research Center have reported the use of a radiolabeled antibody to deliver targeted doses of radiation, followed by a stem cell transplant, to successfully treat a group of leukemia and pre-leukemia patients for whom there previously had been no other curative treatment options.
Van Andel Research Institute (VARI) researchers are one step closer to finding new ways to treat Myelodysplastic Syndrome (MDS), a bone marrow disease that strikes up to 15,000 people each year in the United States, and that sometimes results in acute myeloid leukemia. Researchers found that the gene RhoB is important to the diseaseâ€™s progression and could prove to be a therapeutic target for late-stage MDS.
National Cord Blood Program Provides Stem Cells NEW YORK, Jan.
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.